Introduction
Among the various tumors, the most frequent skin tumors in the Caucasian population, that is, basal cell carcinoma (BCC), squamous cell carcinoma (SCC) or melanoma express Fas-ligand (FasL), [1] [2] [3] [4] [5] a member of the tumor necrosis family, which mediates apoptosis in Fas receptor-expressing target cells. A likely function of FasL on tumor cells is to combat attacking effector cells, for example, T cells, natural killer (NK) cells or macrophages, which express Fas in an activated state. Although direct in vivo evidence for such a tumor escape mechanism is still missing, 6 indirect evidences are available in the BCC model. For example, effector cells seem to be unable to infiltrate the tumor nodules. Indeed, lots of effector cells are found around the BCC nodules, but only very few are detected inside the tumor area. 1 Moreover, forcing the usually Fas-negative BCC to express Fas by intralesionally injected interferon-alpha, leads to extensive apoptosis within the tumor and to tumor regression due to Fas-FasL interaction. 1 Additional in vivo support for an immune escape mechanism comes from mouse experiments. Injection of a FasL + melanoma cell line into Fas-defective lpr-mice resulted in a delayed tumor growth compared to wild-type mice, 5 and in vivo transfection of FasL-specific antisense oligonucleotides (ASO) into growing FasL + colon carcinoma SW620
tumors gave rise to a strongly diminished tumor growth in nude mice. 7 It can be postulated that inhibiting or downregulating FasL expression would deprive BCC of a major defence mechanism and make the tumor cells susceptible to the attack of immune effector cells. Previously, we successfully downregulated FasL expression at the protein and mRNA level in normal skin epidermis and BCC tissues using specific phosphorothiate ASOs. 8 The FasL downregulation resulted in the loss of the apoptosis-inducing function of these cells in vitro.
Recently, chemically synthesized small interfering RNA (siRNA) duplexes were shown to be a powerful tool to specifically silence a gene of interest. 9, 10 This technology is very promising for future therapeutical use, for example, in infectious diseases, cancer or genetic disorders.
11-24 Therefore, we investigated whether it is possible to transfect human BCC tissue with siRNAs and if yes, whether efficient downregulation of FasL expression can be achieved in the tumor tissue. To our knowledge, no study reported efficient siRNA-mediated gene silencing in human tissues so far. Here, we demonstrate that siRNAs can be transfected into BCC tissue and efficiently downregulate endogeneous FasL or heterologous GFP expression with the corresponding specific siRNAs. Our approach now provides the basis to test the FasL-mediated tumor immune evasion model in vivo. In addition, due to its easy accessibility, BCC might be an excellent model system for future siRNA-based therapy.
Results

Downregulation of FasL in cultured cells
HEK 293-005 cells, stably transfected with the FasLexpressing plasmid DNA, were used to demonstrate the potency of FasL downregulation by specific siRNA-F at the cell level. At 2 days post-transfection with either 0.5 mg siRNA-F or the control siRNA-G in the presence of Lipofectamine 2000, FasL expression on HEK293-005 cells was determined by flow cytometry on the protein level. As shown in Figure 1a , FasL-specific siRNA-F downregulated FasL protein expression by about 80%, whereas the control siRNA-G did not, indicating that the inhibition observed is sequence-specific. In support of this specificity, FasL-specific siRNA-F did not induce GFP silencing in GFP-expressing HEK293-GFP cells, whereas siRNA-G did (Figure 1b) . In addition, the specificity of FasL gene silencing was further confirmed by using siRNA-F cognate 2 0 -O-methyl oligonucleotide which acts as a irreversible, stochiometric inhibitor of siRNA. 25 As shown in Figure 1c , siRNA-F-cognate 2 0 -Omethyl oligonucleotide inhibited FasL gene silencing in a dose-dependent manner, whereas the control oligonucleotide had no effect on FasL expression in all concentrations tested, from 1 to 100 nM. To verify that the downregulation of FasL protein expression was indeed siRNA mediated and not due to miRNA-related translational repression of FasL protein synthesis, FasL mRNA degradation was assessed by quantitative TaqMan real-time PCR (Figure 1d) . A similar inhibition (81%) was found on the mRNA level, confirming that the FasL gene silencing observed was mediated by siRNA. Titration experiments with graded concentrations of FasL-specific siRNA-F demonstrated that the downregulation of FasL protein expression was dose-dependent (data not shown).
Transfection of siRNA into BCC tissue
So far, it is unknown whether siRNA can be transfected into human tissues. To address this question, Rhodamine-labeled siRNA targeting GFP (siRNA-G) was used in order to trace the cells transfected by siRNA. Small pieces of surgically excised BCC were cultured in medium containing Rhodamine-labeled siRNA-lipofectamine complexes for 4 days, then cryosections were prepared from the transfected tissues. Rhodamine fluorescence showed that siRNA had spreaded over all parts of the section (Figure 2a ). The comparison with DAPI staining (Figure 2b ) strongly suggested that most of the cells were transfected with Rhodamine-labeled siRNA. To distinguish BCC cells from other cells (Figure 2c ), the same sections were stained with mouse anti-human epithelial antigen Ber-EP4 antibody. The Ber-EP4 immunohistochemical staining clearly demonstrates that most of the Rhodamine-labeled siRNA-transfected ) to study the penetration of siRNA. All crysections showed the same strong Rhodamine labeling in the center of the tissues as at the edges (data not shown), indicating that the bigger BCC tissues were transfected like smaller ones.
To confirm that siRNA was really delivered into cells rather than distributed in the space between the cells or just bound to cellular membranes, 3-D confocal imaging was applied. After dissociation of single cells from BCC tissue transfected with Rhodamine-labeled siRNA by trypsinization, the cells were stained with anti-FasL antibody and Cy2-linked IgG to outline the FasLexpressing cellular membrane (green). As demonstrated by a representative example (Figure 2d ), the images obtained by laser scanning confocal microscopy showed that Rhodamine-labeled siRNA duplexes (red dots) were intracellularly located. A similar set of experiments was carried out with pieces of BCC tissues transfected by pEGFP plasmid DNA rather than Rhodamine-labeled siRNA. GFP expression could be detected in most cells, if not all, in the cryosections (data not shown) supporting the Rhodamine data. All these results clearly demonstrate that cells of the BCC tissue had been transfected.
Downregulation of FasL or GFP expression in BCC tissue
As already mentioned, BCC cells can be transfected to express GFP (Figure 3a) , which is an excellent target to demonstrate siRNA-mediated gene silencing. When GFP-specific siRNA-G was cotransfected with pEGFP plasmid DNA, GFP expression in the BCC was strongly suppressed (Figure 3b ), whereas FasL-specific siRNA-F did not have a significant effect on GFP expression (Figure 3c ). Thus, GFP gene expression was specifically downregulated by siRNA-mediated mechanism, and siRNA can be applied to induce specific gene silencing in human BCC tissue.
To determine siRNA-mediated FasL gene silencing, small pieces of BCC tissue were transfected with FasLspecific siRNA-F or control siRNA-G for 4 days. At the mRNA level, FasL gene silencing by specific siRNA-F was determined by in situ hybridization. In cryosections prepared from BCC tissues only treated with PBSlipofectamine, a high level of FasL mRNA expression was detected with the antisense digoxigenin-labeled Figure 2 Transfection of human BCC tissues with siRNA. Human BCC tissues were cut into small pieces. Each of them was immediately transfected with 0.5 mg Rhodamine-labeled siRNA-G in the presence of lipofectamine and cultured for 2 days. The transfection was repeated and the BCC tissues were cultured for another 2 days. Rhodamine (Rd)-labeled siRNA duplexes were observed in cryosection of BCC tissue (a) and cellular nuclei after DAPI staining (b) by fluorescent microscopy. To confirm BCC cells, the same sections were also stained with mouse Ber-EP4 monoclonal antibodies (c). For confocal imaging, cells dissociated by trypsinization from BCC tissue transfected with Rhodamine-labeled siRNA-G were labeled with anti-human FasL monoclonal antibody and Cy2-linked goat anti-mouse IgG (d). Confocal imaging showed that Rhodamine-labeled siRNA (red dots) was within the BCC cell, which is outlined by Cy2-linked antibody staining (green). Scale bars shown: 100 mm for (a), (b) and (c); 5 mm for (d). (Figure 4a ), but not with the corresponding sense digoxigenin-labeled RNA probe (Figure 4b ), indicating that the observed signal was from the probe that hybridized with the expressed mRNA rather than with the genomic DNA. A similar level of FasL mRNA expression was observed in cryosections transfected with the control siRNA-G (Figure 4d) , whereas a low level of FasL mRNA expression was found in cryosections transfected with the FasL-specific siRNA-F (Figure 4c ). Of interest, a few cells still expressed FasL mRNA in the sections treated with FasL-specific siRNA. These cells most likely were not transfected with siRNA. FasL gene silencing was further confirmed at the protein level, which was analyzed by immunohistochemistry on cryosections. Figure 5 demonstrates that FasL-specific siRNA-F efficiently inhibited FasL protein expression (Figure 5b ), whereas the control siRNA-G (Figure 5c ) or PBS (Figure 5a ) did not. Quantification of FasL downregulation was carried out by computerassisted image analysis. As shown in Figure 5d , FasL expression in siRNA-F-transfected sections was downregulated by almost 70%.
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Discussion
The FasL plays an important role in immune regulation, but is most likely also involved in immune priviledge and immune evasion. Previously, we have succeeded to downregulate FasL expression in BCC tissues using phosphorothiated ASOs. 8 As it has been suggested, that RNA interference, which has been a different mechanism of action from the antisense technology, may be more useful to silence a gene in cancer cells, 26 we investigated whether siRNAs can be transfected into tumor tissue and knock down the gene of interest, FasL in this case. Although the in vitro transfection of cell lines of various mammalian origin with siRNAs has been well established (see some recent reviews [27] [28] [29] ), successful siRNA transfection of human tissues has not been reported so far.
To date, several publications showed that siRNAs are functional in mice and rats even though the delivery of siRNA remains a major problem. 20, 21, [30] [31] [32] [33] In the invertebrate worm Caenorhabditis elegans, introducing RNAi is very simple, for instance, by directly injecting dsRNA, soaking the worm in solutions containing dsRNAs or feeding it with bacteria producing dsRNAs. 34 In mice, some methods have been published to successfully deliver siRNAs. For example, the daily i.p. injection of VEGF-specific siRNA reduced the volume of JT8 tumors growing in nude mice, indicating that the siRNA reached and functioned within the tumor. 35 Or, the hydrodynamic tail vein infusion of Fas-specific siRNAs downregulated Fas expression in the liver over 80% and protected the mice from fulminant hepatitis upon injection with anti-Fas antibodies. 20 In humans, however, it might be for ethical reasons rather difficult to in vivo apply the siRNAs technology at the present time. More knowledge is required about the transfection efficiency and how to best deliver siRNAs. The investigation of human tissues ex vivo is, thus, a prerequisite to test siRNA delivery. Based on the successful application strategy using antisense oligonucleotides, 8 we utilized lipofectamine to enhance the cellular uptake of siRNA duplexes. We tested the transfection of BCC pieces ranging from 1 up to 30 mm 3 without seeing any difference. Our data demonstrate for the first time that siRNA duplexes can be transfected into human BCC tissue and silence the gene under study, that is, GFP or FasL.
Consistent with observations on siRNA-mediated GFP silencing in mice, 32, 36 we found that coculture of BCC tissue with plasmid encoding GFP and its cognate siRNA inhibited GFP gene expression. In cultured indicator cells, the FasL-specific siRNA-F downregulated FasL expression by nearly 80%. In BCC tissue, the FasL downregulation reached almost 70% with the same siRNA-F, indicating a good siRNA transfection. This is consistent with the observation that Rhodamine-labeled siRNA duplexes were found in almost every cells in cryosections (Figure 2) . Fas-ligand gene silencing in basal cell carcinoma J Ji et al Skin diseases or skin tumors might become particularly suitable for a potential siRNA therapy due to their excellent accessibility. Thus, siRNAs can be locally applied instead of systemically, a procedure which may be better controlled and less prone to unwanted side effects. Our results provide the proof of concept that siRNAs can be transfected in BCC tumor tissue and silence the gene of interest. Thus, other tumor-related genes such as Flip or certain members of the bcl-2 family could be knocked down as well and tested for potential tumor growth inhibition. In addition, the immune escape model for BCC can now be tested in vivo. However, before siRNA-based therapy will ultimately be successful in vivo, some important questions have to be answered first, such as the best way of delivery of siRNAs using an experimental model system without ethical constraints.
Materials and methods siRNA and 2 0 -O-methyl oligonucleotides
The FasL-specific siRNA-F was synthesized and IE-HPLC-purified by Qiagen AG (Basel, Switzerland). Its sequence is 5 0 -CUGGGCU GUACU UUGUA UATT-3 0 . As control, GFP-specific siRNA-G or Rhodamine-labeled siRNA-G were obtained from Qiagen AG. 2 0 -O-methyl oligonucleotides were designed to test the specificity of siRNA-mediated gene silencing 25 . FasL-specific 2 0 -Omethyl oligonucleotide (5 0 -aauga aacug ggcug uacuu uguau auucc a-3 0 ) and the control 2 0 -O-methyl oligonucleotide (5 0 -uccca gccca gauga aucac caaaa agggc c-3 0 ) were synthesized and PAGE-purified by DHARMACON (Lafayette, CO, USA).
Cell transfection
FasL-expressing human embryonic kidney HEK293-005 cells, stably transfected with a human FasL expressing plasmid (kindly provided by Dr Pascal Schneider, Institute of Biochemistry, University of Lausanne, Switzerland) were cultured as described elsewhere. 8 A stably GFP-expressing HEK293 cell line was selected with G418 after transfection of pEGFP plasmid DNA (BD Biosciences, Basel, Switzerland). Cells were transfected with 0.5 mg siRNA in the presence of 2 ml Lipofectamine 2000 Reagent (GIBCO Invitrogen, Basel, Switzerland) in 24-well plates according to the manufacturer's protocol for 48 h.
BCC tissue transfection
BCC tissues were obtained either from surgically excised material or from biopsies. The BCC were cut into small pieces, usually about 1 mm in diameter, but some bigger tissues (up to 30 mm 3 and B3 mm in diameter) were also tested. After briefly rinsing with PBS, they were cultured in DMEM (GIBCO Invitrogen, Basel, Switzerland) with Computer-assisted image analysis was performed (d) to quantitate the downregulation of FasL protein expression. The mean intensity value of isotype control was subtracted from those of monoclonal FasL G247-4. Relative gray scale indexes (mean7s.d.) were compared to the mean value of the PBS control, which was set to 1. A total of 10 measurements were made in five different sections.
Fas-ligand gene silencing in basal cell carcinoma J Ji et al 10% fetal bovine serum (FBS) and 0.1 mg/ml gentamicin (GIBCO Invitrogen) at 371C in 5% CO 2 . Transfection with siRNA was performed immediately after obtaining the BCCs and as with cells except that the transfection was repeated after 48 h in order to enhance the siRNA uptake. The transfected BCC tissues were altogether cultured for 4 days.
Flow cytometry
FasL protein expression was stained with mouse antihuman FasL (G247-4) monoclonal antibody (BD Bioscience, Basel, Switzerland) and analyzed with a FACSCalibur flow cytometer (BD Bioscience). GFP protein level was also determined using flow cytometry. A total of 10 000-20 000 cells were investigated. Data were processed with the Cell Quest software.
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TaqMan real-time RT-PCR
The amount of FasL mRNA in cultured cells was determined by quantitative real-time RT-PCR, and standardized by the corresponding GAPDH internal control as described previously. 8 
Confocal microscopy
Single cells were dissociated by trypsinization from transfected BCC tissue and labeled with anti-human FasL monoclonal antibody (BD Bioscience, Basel, Switzerland) and Cy2-linked goat anti-mouse IgG (Amersham Biosciences, Freiburg, Germany). Then, confocal laser scanning microscopy was performed. The images were recorded on a Leica TCS 4D according to NYQUIST theorem.
Immunohistochemistry
Cryosections (8 mm) were prepared from BCC tissues as described previously. 8 The sections were stained with mouse monoclonal antibodies to detect epithelial antigen Ber-EP4 (which stains BCC cells) or FasL (DAKO or BD Bioscience). Secondary biotinylated antibody (Vectastain, Vector Laboratories, Inc., Burlingame, CA, USA) was used before visualization with AEC (DAKO Diagnostics AG, Denmark). Counterstaining was carried out with 1% hematoxylin. As isotype control, the same amount of mouse IgG (DAKO Diagnostics AG, Denmark) was used.
In situ hybridization
Expression of FasL mRNA in BCC tissue was determined by in situ hybridization. Digoxigenin-labeled RNA probes corresponding to codons 86-265 of the human FasL gene were first made. The antisense RNA probe was synthesized from a TOPO II plasmid DNA containing the fragment of FasL gene by in vitro transcription using digoxigenin-11-UTP and T7 RNA polymerase (Roche Molecular Biochemicals, Basel, Switzerland) according to the manufacturer's protocol, while the corresponding control sense RNA probe was synthesized by SP6 RNA polymerase. In situ hybridizations were performed on 8 mm thick BCC cryosections. After hybridization, the digoxigenin-labeled RNA probe was immunologically detected using alkaline phosphataseconjugated sheep anti-digoxigenin antibody (Roche Molecular Biochemicals) and visualized with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphates (NBT/BCIP). In the control hybridizations, the corresponding sense digoxigenin-labeled probe was used.
Computer-assisted image analysis quantification
Details of the procedure to quantify FasL expression in sections of BCC are provided elsewhere. 37 In brief, the immunostained cryosections were photographed and digitalized before couterstaining. For imaging, the equivalent gray-level intensity within the region of interest was determined with the Openlab program (Improvision, Coventry, UK). The mean intensity value of the isotype control was subtracted from the mean intensity values of the FasL antibody. For calculation, the subtracted mean values of the measurements obtained from BCC transfected with FasL-specific siRNA-F or control siRNA-G were normalized to the value of PBS buffer, which was set to 1.0. 37 
